Lexicon Pharma Appoints New Chief Medical Officer
Ticker: LXRX · Form: 8-K · Filed: Sep 16, 2024
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: LXRX
TL;DR
Lexicon Pharma has a new CMO, Dr. Tamara von Koch, starting Sept 16th.
AI Summary
Lexicon Pharmaceuticals, Inc. announced on September 13, 2024, the appointment of Dr. Tamara A. P. von Koch as Chief Medical Officer, effective September 16, 2024. Dr. von Koch previously served as Senior Vice President, Clinical Development at the company. The filing also disclosed the departure of Dr. Jeffrey S. Chiodo as Chief Medical Officer.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's drug development strategy and clinical trial execution.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategic direction or potential challenges in ongoing clinical programs.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- Dr. Tamara A. P. von Koch (person) — Appointed Chief Medical Officer
- September 16, 2024 (date) — Effective date of appointment
- Dr. Jeffrey S. Chiodo (person) — Departing Chief Medical Officer
- September 13, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer at Lexicon Pharmaceuticals?
Dr. Tamara A. P. von Koch has been appointed as the new Chief Medical Officer.
When is the appointment of Dr. Tamara A. P. von Koch effective?
The appointment is effective September 16, 2024.
What was Dr. Tamara A. P. von Koch's previous role at Lexicon Pharmaceuticals?
Dr. von Koch previously served as Senior Vice President, Clinical Development at Lexicon Pharmaceuticals.
Who is departing from the role of Chief Medical Officer?
Dr. Jeffrey S. Chiodo is departing from the role of Chief Medical Officer.
What is the date of this 8-K filing?
The date of the report is September 13, 2024.
Filing Stats: 798 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2024-09-16 06:51:46
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
- $585,000 — al to his current base annual salary of $585,000 for a period of twelve months following
- $175,500 — Wade an additional, lump sum payment of $175,500, or 50% of his current target cash bonu
- $3,700 — ition, we will make monthly payments of $3,700 for a period of 12 months to provide fo
- $3,000 — oyment and we will pay Mr. Wade fees of $3,000 per month. Copies of the separation a
Filing Documents
- lxrx-20240913.htm (8-K) — 27KB
- exh101wadeseparationagreem.htm (EX-10.1) — 20KB
- exh102wadeconsultingagreem.htm (EX-10.2) — 41KB
- 0001062822-24-000051.txt ( ) — 223KB
- lxrx-20240913.xsd (EX-101.SCH) — 2KB
- lxrx-20240913_lab.xml (EX-101.LAB) — 21KB
- lxrx-20240913_pre.xml (EX-101.PRE) — 12KB
- lxrx-20240913_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 — Separation Agreement, dated September 13, 2024, with Jeffrey L. Wade 10.2 — Consulting Agreement, dated September 13, 2024, with Jeffrey L. Wade EX-104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: September 16, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel